Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.55
0.0%
$41.49
$6.71
$64.70
$4.23B1.141.94 million shs3.10 million shs
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$18.09
+4.6%
$15.60
$9.50
$18.85
$1.64B1.61.23 million shs985,700 shs
CytoDyn Inc. stock logo
CYDY
CytoDyn
$0.15
$0.17
$0.13
$0.42
$148.93M0.172.69 million shs423,580 shs
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$10.25
$10.25
$1.40
$10.44
$744.95M-0.331.32 million shsN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.77
+1.9%
$18.89
$10.06
$21.72
$372.07M0.8250,760 shs25,044 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
+0.05%+0.25%+64.16%+231.52%+801.96%
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-0.17%+8.19%+0.46%+22.09%+63.98%
CytoDyn Inc. stock logo
CYDY
CytoDyn
-3.16%+3.52%-8.14%-8.98%-50.63%
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.00%0.00%0.00%+1.59%+472.63%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
+0.62%+4.69%-1.67%+10.47%+78.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
1.4502 of 5 stars
2.13.00.00.02.84.20.0
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
2.2648 of 5 stars
3.52.00.00.03.21.70.6
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.7214 of 5 stars
2.55.00.00.00.51.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
2.27
Hold$50.33-22.02% Downside
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$22.5724.77% Upside
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
2.38
Hold$13.0427.18% Upside
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0021.40% Upside

Current Analyst Ratings

Latest ALPN, NATR, AVDL, CYDY, and GRCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/12/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/9/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
4/9/2024
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
3/19/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$58.88M71.86N/AN/A$5.64 per share11.45
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
$27.96M58.60N/AN/A$0.98 per share18.46
CytoDyn Inc. stock logo
CYDY
CytoDyn
$270K551.59N/AN/A($0.12) per share-1.25
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
$60K12,415.83N/AN/A$2.95 per share3.47
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.84$1.64 per share12.09$8.36 per share2.36

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$160.28M-$2.04N/A21.80N/AN/A-198.06%-84.51%5/2/2024 (Estimated)
CytoDyn Inc. stock logo
CYDY
CytoDyn
-$79.82M-$0.05N/AN/AN/AN/A-478.47%N/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
-$88.08M-$1.05N/AN/AN/AN/A-37.40%-31.24%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.68N/A3.39%12.25%7.75%5/14/2024 (Estimated)

Latest ALPN, NATR, AVDL, CYDY, and GRCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/15/2024Q3 2024
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A-$0.01-$0.01-$0.01N/AN/A
3/18/2024Q4 2023
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
3/4/2024Q4 2023
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/AN/AN/AN/AN/A
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
7.86
7.86
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
N/A
3.64
3.36
CytoDyn Inc. stock logo
CYDY
CytoDyn
N/A
0.08
0.08
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
0.02
7.73
7.73
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14265.55 million37.82 millionOptionable
Avadel Pharmaceuticals plc stock logo
AVDL
Avadel Pharmaceuticals
15490.58 million86.95 millionOptionable
CytoDyn Inc. stock logo
CYDY
CytoDyn
12992.87 million985.82 millionNot Optionable
Gracell Biotechnologies Inc. stock logo
GRCL
Gracell Biotechnologies
31472.68 million52.33 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.90 millionOptionable

ALPN, NATR, AVDL, CYDY, and GRCL Headlines

SourceHeadline
Nature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
finance.yahoo.com - April 23 at 7:40 PM
Natures Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature's Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
globenewswire.com - April 23 at 4:05 PM
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM
Nature’s Sunshine Recognized with Best Company Culture AwardNature’s Sunshine Recognized with Best Company Culture Award
finance.yahoo.com - December 19 at 10:07 AM
Natures Sunshine Products Stock (NASDAQ:NATR), Quotes and News SummaryNatures Sunshine Products Stock (NASDAQ:NATR), Quotes and News Summary
benzinga.com - December 12 at 11:35 PM
Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93
msn.com - November 27 at 7:16 PM
The Return Trends At Natures Sunshine Products (NASDAQ:NATR) Look PromisingThe Return Trends At Nature's Sunshine Products (NASDAQ:NATR) Look Promising
finance.yahoo.com - November 23 at 6:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alpine Immune Sciences logo

Alpine Immune Sciences

NASDAQ:ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Avadel Pharmaceuticals logo

Avadel Pharmaceuticals

NASDAQ:AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
CytoDyn logo

CytoDyn

OTCMKTS:CYDY
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Gracell Biotechnologies logo

Gracell Biotechnologies

NASDAQ:GRCL
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.